Literature DB >> 21122547

Revisiting the past: intra-arterial vasopressin for severe gastrointestinal bleeding in Crohn's disease.

Venkata M B Alla1, Vijayanadh Ojili, Janardhana Gorthi, Attila Csordas, Radha Krishna Yellapu.   

Abstract

Technological advances in the last couple of decades have led to a tremendous improvement in the safety and efficacy of embolization making it the therapeutic intervention of choice in angiogram positive lower gastrointestinal bleeding. Vasopressin has thus been forgotten and it is hardly ever used by the current generation of interventionists. However, coil embolization is technically challenging and requires greater expertise. Difficulty in super-selective catheterization and lack of adequate collateralization can also prevent successful delivery of coils. In this article we present the successful use of intra-arterial vasopressin in a patient with Crohn's disease with severe lower gastrointestinal bleeding. Despite not being the first choice, vasopressin can be safely and effectively used in selected patients who are not candidates for embolotherapy. The purpose of this article is to discuss the relative merits and demerits of vasopressin vis-à-vis embolization and to identify the role of vasopressin in the current era of super-selective embolization. Successful control of massive lower gastrointestinal bleeding by intra-arterial vasopressin infusion has previously been reported only once before in Crohn's disease. We suggest that this technique may be used in an attempt to avoid surgery in these patients.
Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122547     DOI: 10.1016/j.crohns.2010.02.011

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

1.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

2.  Infliximab stopped severe gastrointestinal bleeding in Crohn's disease.

Authors:  Satimai Aniwan; Surasak Eakpongpaisit; Boonlert Imraporn; Surachai Amornsawadwatana; Rungsun Rerknimitr
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 3.  Crohn's disease presenting as acute gastrointestinal hemorrhage.

Authors:  Amareshwar Podugu; Kanwarpreet Tandon; Fernando J Castro
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

Review 4.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

5.  Life-threatening lower gastrointestinal hemorrhage in pediatric Crohn's disease.

Authors:  Earl Kim; Yunkoo Kang; Mi Jung Lee; Young Nyun Park; Hong Koh
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.